{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-030273","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.242664+00:00","generated_at":"2026-06-13T15:36:41.218597+00:00","sec_items":["1.01","3.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcus Biosciences sells 1.01M shares to Gilead at $19.26 per share under amended purchase agreement","bullets":["Gilead to purchase 1,010,000 shares of Arcus common stock at $19.26 per share.","Agreement amends 2021 SPA; Gilead retains option to buy up to 35% of outstanding shares until July 2025.","Shares sold in unregistered transaction under Section 4(a)(2) to accredited investor Gilead.","Closing subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-030273","json":"https://secwatch.observer/filing/0000950170-23-030273.json","markdown":"https://secwatch.observer/filing/0000950170-23-030273.md","text":"https://secwatch.observer/filing/0000950170-23-030273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023030273/0000950170-23-030273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023030273/rcus-20230627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:36:41.218597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eaa93d331a022f282eff9853ac4c8f59b113bb61","claim":"Arcus Biosciences, Inc. amended Second Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2023-06-27).","evidence_excerpt":"On June 27, 2023, Arcus Biosciences, Inc. (“Arcus”) and Gilead Sciences, Inc. (“Gilead”) entered into a Second Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Amended & Restated Common Stock Purchase Agreement entered into between Arcus and Gilead on January 31, 2021 (the “2021 SPA”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023030273/0000950170-23-030273-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Effective","value":"2023-06-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}